{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:15:14Z","timestamp":1793132114778,"version":"4.5.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024078","name":"Kyowa Kirin Farmac\u00e9utica","doi-asserted-by":"publisher","award":["Kyowa Kirin Farmac\u00e9utica"],"award-info":[{"award-number":["Kyowa Kirin Farmac\u00e9utica"]}],"id":[{"id":"10.13039\/501100024078","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypophosphatemia presents with highly variable clinical manifestations. Among the identified hypophosphatemic disorders, X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are caused by persistent excess fibroblast growth factor 23 (FGF23), which leads to phosphate renal wasting and reduced phosphate availability. Traditional treatments involving oral phosphate and active vitamin D supplements have limitations and potential side effects. By targeting FGF23, burosumab directly addresses the underlying pathophysiology of both XLH and TIO. This narrative review describes the diagnosis and management of XLH and TIO, highlighting key gaps and barriers within Italian clinical practice, which are often common in international healthcare settings; pragmatic solutions are also proposed to optimize patient care. Early diagnosis and appropriate treatment of XLH and TIO are crucial for preventing disease progression and improving patient outcomes. However, XLH diagnosis is often delayed or mistaken due to nonspecific symptoms, while TIO diagnosis is complicated by the challenge of localizing small FGF23-secreting tumors, which requires extensive imaging. A general lack of awareness among healthcare professionals about these rare diseases may further delay diagnosis. Management of XLH and TIO also faces hurdles. Although burosumab is now the recommended first-line treatment for XLH patients, both between 1 and 17 years old and adults, its continuous use is often limited by strict eligibility criteria, and adequate follow-up of XLH patients is difficult to maintain during the critical transition period from pediatric age to adulthood. For TIO, tumor resection remains the definitive treatment, but its success depends on tumor localization and surgical expertise. In cases where surgery is not feasible, burosumab or conventional therapy may be used, but long-term management strategies are lacking. Improving the care of XLH and TIO patients requires increased awareness, better access to advanced diagnostic tools, and enhanced multidisciplinary collaboration. Improving networking to discuss clinical cases and share best practices are crucial steps to ensure optimal patient outcomes. Implementing standardized protocols while setting personalized treatment goals and follow-up strategies can significantly improve the quality of life for patients with these rare diseases.<\/jats:p>","DOI":"10.1186\/s13023-025-03952-5","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:03:44Z","timestamp":1759824224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Eller","family":"Vainicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Fintini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"1","key":"3952_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1152\/physiol.00034.2008","volume":"24","author":"T Berndt","year":"2009","unstructured":"Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology. 2009;24(1):17\u201325.","journal-title":"Physiology"},{"issue":"8","key":"3952_CR2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1507\/endocrj.EJ22-0239","volume":"69","author":"T Michigami","year":"2022","unstructured":"Michigami T. Advances in Understanding of phosphate homeostasis and related disorders. Endocr J. 2022;69(8):881\u201396.","journal-title":"Endocr J"},{"issue":"3","key":"3952_CR3","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/JME-20-0121","volume":"65","author":"L Beck","year":"2020","unstructured":"Beck L, Beck-Cormier S. Extracellular phosphate sensing in mammals: what do we know? J Mol Endocrinol. 2020;65(3):R53\u201363.","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"3952_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","volume":"27","author":"MGMG Penido","year":"2012","unstructured":"Penido MGMG, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012;27(11):2039\u201348.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3952_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61(1):91\u2013104.","journal-title":"Annu Rev Med"},{"issue":"8","key":"3952_CR6","doi-asserted-by":"publisher","first-page":"e10190","DOI":"10.1002\/jbm4.10190","volume":"3","author":"EA Imel","year":"2019","unstructured":"Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, hypophosphatemia, and emerging treatments. JBMR Plus. 2019;3(8):e10190.","journal-title":"JBMR Plus"},{"issue":"5","key":"3952_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00223-012-9651-0","volume":"91","author":"JM Pettifor","year":"2012","unstructured":"Pettifor JM, Thandrayen K. Hypophosphatemic rickets: unraveling the role of FGF23. Calcif Tissue Int. 2012;91(5):297\u2013306.","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"3952_CR8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/clinchem\/34.8.1622","volume":"34","author":"G Lockitch","year":"1988","unstructured":"Lockitch G, Halstead AC, Albersheim S, MacCallum C, Quigley G. Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem. 1988;34(8):1622\u20135.","journal-title":"Clin Chem"},{"issue":"3","key":"3952_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012;97(3):696\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3952_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2213-8587(19)30426-7","volume":"8","author":"P Florenzano","year":"2020","unstructured":"Florenzano P, Cipriani C, Roszko KL, Fukumoto S, Collins MT, Minisola S, Pepe J. Approach to patients with hypophosphataemia. Lancet Diabetes Endocrinol. 2020;8(2):163\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3952_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int. 2021;32(10):1937\u201349.","journal-title":"Osteoporos Int"},{"issue":"7","key":"3952_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"3952_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1210\/er.2017-00220","volume":"39","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Fukumoto S, X-Linked Hypophosphatemia. FGF23-Related hypophosphatemic diseases: prospect for new treatment. Endocr Rev. 2018;39(3):274\u201391.","journal-title":"Endocr Rev"},{"key":"3952_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","volume":"21","author":"D Haffner","year":"2025","unstructured":"Haffner D, Emma F, Seefried L, H\u00f6gler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Duplan MB, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenick\u00fd P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025;21:330\u201354. https:\/\/doi.org\/10.1038\/s41581-024-00926-x.","journal-title":"Nat Rev Nephrol"},{"key":"3952_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4614-0887-1_3","volume-title":"Endocrine FGFs and klothos. Advances in experimental medicine and biology","author":"C Bergwitz","year":"2012","unstructured":"Bergwitz C, J\u00fcppner H. FGF23 and syndromes of abnormal renal phosphate handling. In: Kuro-o M, editor. Endocrine FGFs and klothos. Advances in experimental medicine and biology. Volume 728. New York, NY: Springer US; 2012. pp. 41\u201364."},{"issue":"3","key":"3952_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12020-022-03039-2","volume":"76","author":"L Cianferotti","year":"2022","unstructured":"Cianferotti L, Delli Poggi C, Bertoldo F, Caffarelli C, Crotti C, Gatti D, Giannini S, Gonnelli S, Mazzantini M, Ombretta V, Sella S, Setti A, Varenna M, Zucchi F, Brandi ML. Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a National survey\/case series. Endocrine. 2022;76(3):709\u201321.","journal-title":"Endocrine"},{"issue":"2","key":"3952_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3803\/EnM.2023.1908","volume":"39","author":"N Ito","year":"2024","unstructured":"Ito N, Hidaka N, Kato H. Acquired forms of fibroblast growth factor 23-Related hypophosphatemic osteomalacia. Endocrinol Metab. 2024;39(2):255\u201361. https:\/\/doi.org\/10.3803\/EnM.2023.1908.","journal-title":"Endocrinol Metab"},{"issue":"4","key":"3952_CR18","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587\u201397.","journal-title":"J Clin Invest"},{"issue":"6","key":"3952_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN. Burosumab: first global approval. Drugs. 2018;78(6):707\u201314.","journal-title":"Drugs"},{"key":"3952_CR20","unstructured":"Crysvita Summary of Product Characteristics [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf"},{"key":"3952_CR21","doi-asserted-by":"publisher","first-page":"101725","DOI":"10.1016\/j.bonr.2023.101725","volume":"20","author":"L Abebe","year":"2024","unstructured":"Abebe L, Phung K, Robinson ME, Waldner R, Carsen S, Smit K, Tice A, Lazier J, Armour C, Page M, Dover S, Rauch F, Koujok K, Ward LM. Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome. Bone Rep. 2024;20:101725.","journal-title":"Bone Rep"},{"key":"3952_CR22","doi-asserted-by":"publisher","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","volume":"150","author":"A Gladding","year":"2021","unstructured":"Gladding A, Szymczuk V, Auble BA, Boyce AM. Burosumab treatment for fibrous dysplasia. Bone. 2021;150:116004.","journal-title":"Bone"},{"issue":"2","key":"3952_CR23","doi-asserted-by":"publisher","first-page":"101826","DOI":"10.1016\/j.beem.2023.101826","volume":"38","author":"A Goyal","year":"2024","unstructured":"Goyal A, Tandon N. Burosumab: current status and future prospects. Best Pract Res Clin Endocrinol Metab. 2024;38(2):101826.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3952_CR24","unstructured":"Ipofosfatemia legata all\u2019X. burosumab disponibile in Italia anche per pazienti adulti. Available from: https:\/\/www.osservatoriomalattierare.it\/malattie-rare\/rachitismo-ipofosfatemico\/19674-ipofosfatemia-legata-all-x-burosumab-disponibile-in-italia-anche-per-pazienti-adulti"},{"key":"3952_CR25","doi-asserted-by":"crossref","unstructured":"Ali DS, Carpenter TO, Imel EA, Ward LM, Appelman-Dijkstra NM, Chaussain C, De Beur SMJ, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rao C, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Guyatt G, Brandi ML, Khan AA. X-Linked hypophosphatemia management in children: an international working group clinical practice guideline. J Clin Endocrinol Metab. 2025. dgaf093. Online ahead of print.","DOI":"10.1210\/clinem\/dgaf093"},{"key":"3952_CR26","doi-asserted-by":"crossref","unstructured":"Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan De Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked hypophosphatemia management in adults: an international working group clinical practice guideline. J Clin Endocrinol Metab. 2025;dgaf170.","DOI":"10.1210\/clinem\/dgaf170"},{"issue":"1","key":"3952_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","volume":"18","author":"G Ariceta","year":"2023","unstructured":"Ariceta G, Beck-Nielsen SS, Boot AM, Brandi ML, Briot K, De Lucas Collantes C, Emma F, Giannini S, Haffner D, Keen R, Levtchenko E, M\u04d3kitie O, Mughal MZ, Nilsson O, Schnabel D, Tripto-Shkolnik L, Liu J, Williams A, Wood S, Zillikens MC. The international X-Linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data. Orphanet J Rare Dis. 2023;18(1):304.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3952_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, De Lucas Collantes C, Schnabel D, Jandhyala R, M\u00e4kitie O. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3952_CR29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan De Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Min Res. 2011;26(7):1381\u20138.","journal-title":"J Bone Min Res"},{"issue":"2","key":"3952_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.7326\/0003-4819-100-2-230","volume":"100","author":"M Davies","year":"1984","unstructured":"Davies M. Impaired hearing in X-Linked hypophosphataemic (Vitamin-D-Resistant) osteomalacia. Ann Intern Med. 1984;100(2):230.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3952_CR31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C, San Martin J. The lifelong impact of X-Linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321\u201334.","journal-title":"J Endocr Soc"},{"issue":"6","key":"3952_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3171\/2015.10.PEDS15273","volume":"17","author":"RA Vega","year":"2016","unstructured":"Vega RA, Opalak C, Harshbarger RJ, Fearon JA, Ritter AM, Collins JJ, Rhodes JL. Hypophosphatemic rickets and craniosynostosis: a multicenter case series. J Neurosurg Pediatr. 2016;17(6):694\u2013700.","journal-title":"J Neurosurg Pediatr"},{"key":"3952_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2016.11.019","volume":"95","author":"T Boukpessi","year":"2017","unstructured":"Boukpessi T, Hoac B, Coyac BR, Leger T, Garcia C, Wicart P, Whyte MP, Glorieux FH, Linglart A, Chaussain C, McKee MD. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone. 2017;95:151\u201361.","journal-title":"Bone"},{"issue":"1","key":"3952_CR34","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Pri\u00e9 D, Rothenbuhler A, Wicart P, Harvengt P. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13\u201330.","journal-title":"Endocr Connect"},{"issue":"2","key":"3952_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/20469047.2016.1248170","volume":"37","author":"AL Creo","year":"2017","unstructured":"Creo AL, Thacher TD, Pettifor JM, Strand MA, Fischer PR. Nutritional rickets around the world: an update. Paediatrics Int Child Health. 2017;37(2):84\u201398.","journal-title":"Paediatrics Int Child Health"},{"issue":"1","key":"3952_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan De Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O\u2019Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW. Most Osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1\u201330.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"3952_CR37","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","volume":"59","author":"N Weidner","year":"1987","unstructured":"Weidner N, Cruz DS. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59(8):1442\u201354.","journal-title":"Cancer"},{"issue":"9","key":"3952_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811\u20136.","journal-title":"Endocr J"},{"key":"3952_CR39","doi-asserted-by":"crossref","unstructured":"Jiang Y, Xia W, ping bo, Xing X, Silva BC, Li M, Wang O, Zhang H bing, Li F, Jing H, li, Zhong Drong, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng X. wu. Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res. 2012;27(9):1967\u201375.","DOI":"10.1002\/jbmr.1642"},{"issue":"2","key":"3952_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","volume":"109","author":"B Abrahamsen","year":"2021","unstructured":"Abrahamsen B, Smith CD, Minisola S. Epidemiology of Tumor-Induced osteomalacia in Denmark. Calcif Tissue Int. 2021;109(2):147\u201356.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"3952_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","volume":"111","author":"A Bosman","year":"2022","unstructured":"Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S, Xia W, Body JJ, Zillikens MC. Tumor-Induced osteomalacia: A systematic clinical review of 895 cases. Calcif Tissue Int. 2022;111(4):367\u201379.","journal-title":"Calcif Tissue Int"},{"key":"3952_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017;7:90\u20137.","journal-title":"Bone Rep"},{"issue":"7","key":"3952_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","volume":"64","author":"J Feng","year":"2017","unstructured":"Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, Li F, Yu W, Zhong Drong, Jin J, Liu Y, Qi F, Lv W, Zhou L. Meng X wu, Xia W bo. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017;64(7):675\u201383.","journal-title":"Endocr J"},{"issue":"9","key":"3952_CR44","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00198-022-06432-9","volume":"33","author":"S Minisola","year":"2022","unstructured":"Minisola S, Barlassina A, Vincent SA, Wood S, Williams A. A literature review to understand the burden of disease in people living with tumour-induced osteomalacia. Osteoporos Int. 2022;33(9):1845\u201357.","journal-title":"Osteoporos Int"},{"key":"3952_CR45","doi-asserted-by":"publisher","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P, De Jan SM, Minisola S, Oheim R, Seefried L. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021;152:116064.","journal-title":"Bone"},{"issue":"3","key":"3952_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/joim.13593","volume":"293","author":"SM De Jan","year":"2023","unstructured":"De Jan SM, Minisola S, Xia W, Abrahamsen B, Body J, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S. Global guidance for the recognition, diagnosis, and management of tumor\u2010induced osteomalacia. J Intern Med. 2023;293(3):309\u201328.","journal-title":"J Intern Med"},{"issue":"2","key":"3952_CR47","doi-asserted-by":"publisher","first-page":"e10580","DOI":"10.1002\/jbm4.10580","volume":"6","author":"J DeCorte","year":"2022","unstructured":"DeCorte J, Randazzo E, Black M, Hendrickson C, Dahir K. Rare diseases that impersonate one another: X-Linked hypophosphatemia and Tumor-Induced osteomalacia, a retrospective analysis of discriminating features. JBMR Plus. 2022;6(2):e10580.","journal-title":"JBMR Plus"},{"issue":"9","key":"3952_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/jbmr.4331","volume":"36","author":"R Jiajue","year":"2020","unstructured":"Jiajue R, Ni X, Jin C, Huo L, Wu H, Liu Y, Jin J, Yu W, Lv W, Zhou L, Xia Y, Chi Y, Cui L, Pang Q, Li X, Jiang Y, Wang O, Li M, Xing X, Meng X, Xia W. Early discrimination between Tumor-Induced rickets\/osteomalacia and X-Linked hypophosphatemia in Chinese children and adolescents: A retrospective Case\u2013Control study. J Bone Min Res. 2020;36(9):1739\u201348.","journal-title":"J Bone Min Res"},{"issue":"1","key":"3952_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3345\/cep.2022.01459","volume":"67","author":"E Park","year":"2024","unstructured":"Park E, Kang HG. X-linked hypophosphatemic rickets: from diagnosis to management. Clin Exp Pediatr. 2024;67(1):17\u201325.","journal-title":"Clin Exp Pediatr"},{"issue":"2","key":"3952_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.57582\/IJBF.210102.059","volume":"1","author":"A De Cicco","year":"2021","unstructured":"De Cicco A, Toro G, Grandone A, Braile A, Landi G, Iolascon G, Del Miraglia E, Schiavone Panni A. X-linked hypophosphatemic rickets. What the orthopedic surgeon needs to know. Int J Bone Frag. 2021;1(2):59\u201366.","journal-title":"Int J Bone Frag"},{"issue":"10","key":"3952_CR51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00402-007-0548-8","volume":"128","author":"H Matsubara","year":"2008","unstructured":"Matsubara H, Tsuchiya H, Kabata T, Sakurakichi K, Watanabe K, Tomita K. Deformity correction for vitamin D-resistant hypophosphatemic rickets of adults. Arch Orthop Trauma Surg. 2008;128(10):1137\u201343.","journal-title":"Arch Orthop Trauma Surg"},{"issue":"7","key":"3952_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5435\/JAAOS-D-14-00082","volume":"23","author":"MS Sharkey","year":"2015","unstructured":"Sharkey MS, Grunseich K, Carpenter TO. Contemporary medical and surgical management of X-linked hypophosphatemic rickets. J Am Acad Orthop Surg. 2015;23(7):433\u201342.","journal-title":"J Am Acad Orthop Surg"},{"issue":"8","key":"3952_CR53","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1530\/EC-17-0154","volume":"6","author":"A Gizard","year":"2017","unstructured":"Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, De Billy B, Linglart A, Wicart P. Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr Connect. 2017;6(8):566\u201373.","journal-title":"Endocr Connect"},{"issue":"9","key":"3952_CR54","doi-asserted-by":"publisher","first-page":"bvab099","DOI":"10.1210\/jendso\/bvab099","volume":"5","author":"K Dahir","year":"2021","unstructured":"Dahir K, Zanchetta MB, Stanciu I, Robinson C, Lee JY, Dhaliwal R, Charles J, Civitelli R, Roberts MS, Krolczyk S, Weber T. Diagnosis and management of Tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc. 2021;5(9):bvab099.","journal-title":"J Endocr Soc"},{"issue":"11","key":"3952_CR55","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/CM9.0000000000001448","volume":"134","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Li X, Huo L, Liu Y, Lyu W, Zhou L, Yu W, Wu HW, Xing XP, Li M, Wang O, Chi Y, Jiajue RZ, Pei Y, Liu JM, Ba JM, Zhang Q, Sheng ZF, Zhang ZL, Zhao JJ, Minisola S, Xia WB. Consensus on clinical management of tumor-induced osteomalacia. Chin Med J. 2021;134(11):1264\u20136.","journal-title":"Chin Med J"},{"issue":"2","key":"3952_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1210\/endrev\/bnac026","volume":"44","author":"S Minisola","year":"2023","unstructured":"Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV. Tumor-induced osteomalacia: A comprehensive review. Endocr Rev. 2023;44(2):323\u201353.","journal-title":"Endocr Rev"},{"issue":"3","key":"3952_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2020","unstructured":"Li X, Jiang Y, Huo L, Wu H, Liu Y, Jin J, Yu W, Lv W, Zhou L, Xia Y, Wang O, Li M, Xing X, Chi Y, Jiajue R, Cui L, Meng X, Xia W. Nonremission and recurrent Tumor-Induced osteomalacia: A retrospective study. J Bone Min Res. 2020;35(3):469\u201377.","journal-title":"J Bone Min Res"},{"issue":"7","key":"3952_CR58","doi-asserted-by":"publisher","first-page":"e10178","DOI":"10.1002\/jbm4.10178","volume":"3","author":"SK Mishra","year":"2019","unstructured":"Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A. Successful management of Tumor-Induced osteomalacia with radiofrequency ablation: A case series. JBMR Plus. 2019;3(7):e10178.","journal-title":"JBMR Plus"},{"issue":"11","key":"3952_CR59","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/jbmr.3219","volume":"32","author":"SH Tella","year":"2017","unstructured":"Tella SH, Amalou H, Wood BJ, Chang R, Chen CC, Robinson C, Millwood M, Guthrie LC, Xu S, Levy E, Krishnasamy V, Gafni RI, Collins MT. Multimodality Image-Guided cryoablation for inoperable Tumor-Induced osteomalacia. J Bone Min Res. 2017;32(11):2248\u201356.","journal-title":"J Bone Min Res"},{"issue":"10","key":"3952_CR60","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1210\/jc.2012-1719","volume":"97","author":"S Tutton","year":"2012","unstructured":"Tutton S, Olson E, King D, Shaker JL. Successful treatment of Tumor-Induced osteomalacia with CT-Guided percutaneous ethanol and cryoablation. J Clin Endocrinol Metab. 2012;97(10):3421\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"3952_CR61","doi-asserted-by":"crossref","first-page":"8841259","DOI":"10.1155\/2021\/8841259","volume":"2021","author":"M Massaccesi","year":"2021","unstructured":"Massaccesi M, Miccich\u00e8 F, Rigante M, Petrone G, Lepre E, Gambacorta MA, Valentini V. Successful treatment of tumor-Induced osteomalacia by multidisciplinary therapy with radiation to intracranial fibromyxoid tumor. Case Rep Endocrinol. 2021;2021:8841259.","journal-title":"Case Rep Endocrinol"},{"key":"3952_CR62","doi-asserted-by":"publisher","first-page":"101142","DOI":"10.1016\/j.bonr.2021.101142","volume":"15","author":"MT Kilbane","year":"2021","unstructured":"Kilbane MT, Crowley R, Heffernan E, D\u2019Arcy C, O\u2019Toole G, Twomey PJ, McKenna MJ. High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series. Bone Rep. 2021;15:101142.","journal-title":"Bone Rep"},{"issue":"22","key":"3952_CR63","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJM200205303462215","volume":"346","author":"Octreotide for Tumor-Induced Osteomalacia","year":"2002","unstructured":"Octreotide for Tumor-Induced Osteomalacia. N Engl J Med. 2002;346(22):1748\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"3952_CR64","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/jbmr.3162","volume":"32","author":"D Ovejero","year":"2017","unstructured":"Ovejero D, El-Maouche D, Brillante BA, Khosravi A, Gafni RI, Collins MT. Octreotide is ineffective in treating Tumor-Induced osteomalacia: results of a Short-Term therapy. J Bone Min Res. 2017;32(8):1667\u201371.","journal-title":"J Bone Min Res"},{"issue":"26","key":"3952_CR65","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa010839","volume":"345","author":"J Seufert","year":"2001","unstructured":"Seufert J, Ebert K, M\u00fcller J, Eulert J, Hendrich C, Werner E, Sch\u00fctze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F. Octreotide therapy for Tumor-Induced osteomalacia. N Engl J Med. 2001;345(26):1883\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"3952_CR66","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrow R, Zhang JH, Carpenter TO. Conventional therapy in adults with X-Linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab. 2015;100(10):3625\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3952_CR67","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107(8):e3241\u201353.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3952_CR68","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.2009-1671","volume":"95","author":"EA Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-Linked hypophosphatemia with calcitriol and phosphate increases Circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"3952_CR69","first-page":"263300402210747","volume":"3","author":"MH Lafage-Proust","year":"2022","unstructured":"Lafage-Proust MH. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review. Ther Adv Rare Dis. 2022;3:263300402210747.","journal-title":"Ther Adv Rare Dis"},{"issue":"1","key":"3952_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/endocrines4010010","volume":"4","author":"H Zukeran","year":"2023","unstructured":"Zukeran H, Ikegawa K, Numakura C, Hasegawa Y. The possible outcomes of poor adherence to conventional treatment in patients with X-Linked hypophosphatemic rickets\/osteomalacia. Endocrines. 2023;4(1):110\u20136.","journal-title":"Endocrines"},{"issue":"21","key":"3952_CR71","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, Padidela R, Van \u2018T, Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab therapy in children with X-Linked hypophosphatemia. N Engl J Med. 2018;378(21):1987\u201398.","journal-title":"N Engl J Med"},{"issue":"10189","key":"3952_CR72","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416\u201327.","journal-title":"Lancet"},{"issue":"3","key":"3952_CR73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA. Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3952_CR74","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM, Padidela R, Van \u2018T, Hoff W, Gottesman GS, Chen A, Skrinar A, Scott Roberts M, Carpenter TO. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-Linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107(3):813\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3952_CR75","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Williams A, Nixon A, Sun W, Chen A, Skrinar A, Imel EA. Patient-Reported outcomes from a randomized, Active-Controlled, Open-Label, phase 3 trial of burosumab versus conventional therapy in children with X-Linked hypophosphatemia. Calcif Tissue Int. 2021;108(5):622\u201333.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"3952_CR76","doi-asserted-by":"publisher","first-page":"bvac021","DOI":"10.1210\/jendso\/bvac021","volume":"6","author":"N Namba","year":"2022","unstructured":"Namba N, Kubota T, Muroya K, Tanaka H, Kanematsu M, Kojima M, Orihara S, Kanda H, Seino Y, Ozono K. Safety and efficacy of burosumab in pediatric patients with X-Linked hypophosphatemia: A phase 3\/4 Open-Label trial. J Endocr Soc. 2022;6(5):bvac021.","journal-title":"J Endocr Soc"},{"issue":"4","key":"3952_CR77","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12325-022-02412-x","volume":"40","author":"T Kubota","year":"2023","unstructured":"Kubota T, Namba N, Tanaka H, Muroya K, Imanishi Y, Takeuchi Y, Kanematsu M, Sun W, Seino Y, Ozono K. Self-Administration of burosumab in children and adults with X-Linked hypophosphataemia in two Open-Label, Single-Arm clinical studies. Adv Ther. 2023;40(4):1530\u201345.","journal-title":"Adv Ther"},{"issue":"11","key":"3952_CR78","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","volume":"108","author":"EA Imel","year":"2023","unstructured":"Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Chen A, Roberts MS, Ward LM. Burosumab vs phosphate\/active vitamin D in pediatric X-Linked hypophosphatemia: A subgroup analysis by dose level. J Clin Endocrinol Metab. 2023;108(11):2990\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"3952_CR79","doi-asserted-by":"crossref","unstructured":"Ward LM, H\u00f6gler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Sochett E, Muroya K, Tanaka H, Pitukcheewanont P, Gottesman GS, Biggin A, Perwad F, Chen A, Lawrence Merritt Ii, Imel J. EA. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024;8(1):ziad001.","DOI":"10.1093\/jbmrpl\/ziad001"},{"issue":"8","key":"3952_CR80","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan De Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO. On behalf of the AXLES 1 investigators. A randomized, Double-Blind, Placebo-Controlled, phase 3 trial evaluating the efficacy of burosumab, an Anti-FGF23 antibody, in adults with X-Linked hypophosphatemia: week 24 primary analysis. J Bone Min Res. 2018;33(8):1383\u201393.","journal-title":"J Bone Min Res"},{"issue":"12","key":"3952_CR81","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab improved histomorphometric measures of osteomalacia in adults with X-Linked hypophosphatemia: A phase 3, Single-Arm, international trial. J Bone Min Res. 2019;34(12):2183\u201391.","journal-title":"J Bone Min Res"},{"issue":"1","key":"3952_CR82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2022","unstructured":"Weber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, Merritt JL, Insogna K. Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;108(1):155\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3952_CR83","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued beneficial effects of burosumab in adults with X-Linked hypophosphatemia: results from a 24-Week treatment continuation period after a 24-Week Double-Blind Placebo-Controlled period. Calcif Tissue Int. 2019;105(3):271\u201384.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"3952_CR84","doi-asserted-by":"publisher","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan De Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021;7(3):e001714.","journal-title":"RMD Open"},{"issue":"4","key":"3952_CR85","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","volume":"111","author":"ML Brandi","year":"2022","unstructured":"Brandi ML, De Beur J, Briot S, Carpenter K, Cheong T, Cohen-Solal HI, Crowley M, Eastell RK, Imanishi R, Imel Y, Ing EA, Insogna SW, Ito K, Javaid N, Kamenicky K, Keen P, Kubota R, Lachmann T, Perwad RH, Pitukcheewanont F, Portale P, Ralston A, Tanaka SH, Weber H, Yoo TJ, Sun HW, Williams W, Nixon A, Takeuchi A. Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): A post hoc subgroup analysis of a randomized Double-Blind Placebo-Controlled phase 3 study. Calcif Tissue Int. 2022;111(4):409\u201318.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"3952_CR86","doi-asserted-by":"publisher","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S, Lachmann RH, Lecoq AL, Ralston SH, Walsh JS, Rylands AJ, Williams A, Sun W, Nixon A, Nixon M, Javaid MK. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. 2023;9(1):e002676.","journal-title":"RMD Open"},{"issue":"2","key":"3952_CR87","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2020","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim analysis of a phase 2 Open-Label trial assessing burosumab efficacy and safety in patients with Tumor-Induced osteomalacia. J Bone Min Res. 2020;36(2):262\u201370.","journal-title":"J Bone Min Res"},{"issue":"4","key":"3952_CR88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM De Jan","year":"2020","unstructured":"De Jan SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the treatment of Tumor-Induced osteomalacia. J Bone Min Res. 2020;36(4):627\u201335.","journal-title":"J Bone Min Res"},{"issue":"11","key":"3952_CR89","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jbmr.4900","volume":"38","author":"SM De Jan","year":"2023","unstructured":"De Jan SM, Cimms T, Nixon A, Theodore-Oklota C, Luca D, Roberts MS, Egan S, Graham CA, Hribal E, Evans CJ, Wood S, Williams A. Burosumab improves Patient-Reported outcomes in adults with Tumor-Induced osteomalacia: Mixed-Methods analysis. J Bone Min Res. 2023;38(11):1654\u201364.","journal-title":"J Bone Min Res"},{"key":"3952_CR90","first-page":"204201882110011","volume":"12","author":"A Brener","year":"2021","unstructured":"Brener A, Lebenthal Y, Cleper R, Kapusta L, Zeitlin L. Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol. 2021;12:204201882110011.","journal-title":"Ther Adv Endocrinol"},{"issue":"10","key":"3952_CR91","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert A, Rehberg M, Schlingmann KP, Hiort O, John-Kroegel U, Metzing O, W\u00fchl E, Schaefer F, Kemper MJ, Derichs U, Richter-Unruh A, Patzer L, Albers N, Dunstheimer D, Haberland H, Heger S, Schr\u00f6der C, Jorch N, Schmid E, Staude H, Weitz M, Freiberg C, Leifheit-Nestler M, Zivicnjak M, Schnabel D, Haffner D. Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2023;108(10):e998\u20131006.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"3952_CR92","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","volume":"37","author":"NJ Paloian","year":"2022","unstructured":"Paloian NJ, Nemeth B, Sharafinski M, Modaff P, Steiner RD. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2022;37(11):2667\u201377.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"3952_CR93","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","volume":"108","author":"EYX Walker","year":"2023","unstructured":"Walker EYX, Lindsay TAJ, Allgrove J, Marlais M, Bockenhauer D, Hayes W. Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels. Arch Dis Child. 2023;108(5):379\u201384.","journal-title":"Arch Dis Child"},{"issue":"11","key":"3952_CR94","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00467-024-06427-0","volume":"39","author":"M Klein","year":"2024","unstructured":"Klein M, Obermaier M, Mutze H, Wilden SM, Rehberg M, Schlingmann KP, Schmidt D, Metzing O, H\u00fcbner A, Richter-Unruh A, Kemper MJ, Weitz M, W\u00fchl E, Jorch N, Patzer L, Freiberg C, Heger S, Ziviknjak M, Schnabel D, Haffner D. On behalf of the German society for pediatric nephrology (GPN) and the German society for pediatric and adolescent endocrinology and diabetology (DGPAED). Health-related quality of life of children with X-linked hypophosphatemia in Germany. Pediatr Nephrol. 2024;39(11):3221\u201331.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"3952_CR95","doi-asserted-by":"publisher","first-page":"ziae079","DOI":"10.1093\/jbmrpl\/ziae079","volume":"8","author":"T Michigami","year":"2024","unstructured":"Michigami T, Kang HG, Namba N, Ito N, Kubota T, Shintani A, Kabata D, Kanematsu M, Nishida Y, Fukumoto S, Ozono K. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024;8(8):ziae079.","journal-title":"JBMR Plus"},{"issue":"2","key":"3952_CR96","doi-asserted-by":"publisher","first-page":"e2387","DOI":"10.1002\/mgg3.2387","volume":"12","author":"MH Vaisbich","year":"2024","unstructured":"Vaisbich MH, De Cillo ACP, Silva BCC, D\u00c1lva CB, De Carvalho \u00c9H, De Almeida JMCM, Marques LLM, Ribeiro M, Da Silva MBM, De Medeiros PFV, Mendes PH. Real-world data of Brazilian adults with X\u2010linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts. Mol Genet Genomic Med. 2024;12(2):e2387.","journal-title":"Mol Genet Genomic Med"},{"issue":"11","key":"3952_CR97","doi-asserted-by":"publisher","first-page":"e250237","DOI":"10.1136\/bcr-2022-250237","volume":"15","author":"R Barai","year":"2022","unstructured":"Barai R, Tsang T, Cespedes L. Tumour-induced osteomalacia due to residual benign glomangioma. BMJ Case Rep. 2022;15(11):e250237.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"3952_CR98","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00198-022-06516-6","volume":"34","author":"C Crotti","year":"2023","unstructured":"Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M. Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. 2023;34(1):201\u20136.","journal-title":"Osteoporos Int"},{"key":"3952_CR99","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2147\/IMCRJ.S425599","volume":"16","author":"Y Horinouchi","year":"2023","unstructured":"Horinouchi Y, Shiota S, Kaimori R, Yoshimura K, Utsunomiya-Nishimizu R, Yamamoto K, Miyazaki E. A case of Tumor-Induced osteomalacia detected by venous sampling. IMCRJ. 2023;16:659\u201365.","journal-title":"IMCRJ"},{"key":"3952_CR100","doi-asserted-by":"publisher","first-page":"101772","DOI":"10.1016\/j.bonr.2024.101772","volume":"21","author":"N \u00c1lvarez-Rivas","year":"2024","unstructured":"\u00c1lvarez-Rivas N, Lugo-Rodr\u00edguez G, Maneiro JR, I\u00f1iguez-Ubiaga C, Melero-Gonzalez RB, Iglesias-Cabo T, Carmona L, Garc\u00eda-Porr\u00faa C, De Toro-Santos FJ. Tumor-induced osteomalacia: A systematic literature review. Bone Rep. 2024;21:101772.","journal-title":"Bone Rep"},{"key":"3952_CR101","doi-asserted-by":"publisher","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","volume":"13","author":"MZ Mughal","year":"2023","unstructured":"Mughal MZ, Baroncelli GI, De Lucas-Collantes C, Linglart A, Magnolato A, Raimann A, Santos F, Schnabel D, Shaw N, Nilsson O. Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries. Front Endocrinol. 2023;13:1034580.","journal-title":"Front Endocrinol"},{"issue":"6","key":"3952_CR102","doi-asserted-by":"publisher","first-page":"e10744","DOI":"10.1002\/jbm4.10744","volume":"7","author":"CF Munns","year":"2023","unstructured":"Munns CF, Yoo H, Jalaludin MY, Vasanwala R, Chandran M, Rhee Y, But WM, Kong AP, Su P, Numbenjapon N, Namba N, Imanishi Y, Clifton-Bligh RJ, Luo X, Xia W. Asia\u2010Pacific consensus recommendations on X\u2010Linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care. JBMR Plus. 2023;7(6):e10744.","journal-title":"JBMR Plus"},{"issue":"5","key":"3952_CR103","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jpc.15976","volume":"58","author":"JL Sandy","year":"2022","unstructured":"Sandy JL, Simm PJ, Biggin A, Rodda CP, Wall C, Siafarikas A, Munns CF. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab. J Paediatrics Child Health. 2022;58(5):762\u20138.","journal-title":"J Paediatrics Child Health"},{"issue":"6","key":"3952_CR104","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML, Cannata-And\u00eda JB, Cavalier E, Chandran M, Chaussain C, Cipullo L, Cooper C, Haffner D, Harvengt P, Harvey NC, Javaid MK, Jiwa F, Kanis JA, Laslop A, Laurent MR, Linglart A, Marques A, Mindler GT, Minisola S, Yerro MCP, Rosa MM, Seefried L, Vlaskovska M, Zanchetta MB, Rizzoli R. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol. 2022;18(6):366\u201384.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"3952_CR105","doi-asserted-by":"publisher","first-page":"e10692","DOI":"10.1002\/jbm4.10692","volume":"6","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, Black M, Gottesman GS, Imel EA, Mumm S, Nichols CM, Whyte MP. X-Linked hypophosphatemia caused by the prevailing North American PHEX variant c.*231A\u2009>\u2009G; exon 13\u201315 duplication is often misdiagnosed as ankylosing spondylitis and manifests in both men and women. JBMR Plus. 2022;6(12):e10692.","journal-title":"JBMR Plus"},{"issue":"7","key":"3952_CR106","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.arcped.2021.09.005","volume":"28","author":"NAT Hamdy","year":"2021","unstructured":"Hamdy NAT, Harvengt P, Usardi A. X-linked hypophosphatemia: the medical expert\u2019s challenges and the patient\u2019s concerns on their journey with the disease. Archives De P\u00e9diatrie. 2021;28(7):612\u20138.","journal-title":"Archives De P\u00e9diatrie"},{"issue":"6","key":"3952_CR107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"AS Lambert","year":"2019","unstructured":"Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine. 2019;86(6):731\u20138.","journal-title":"Joint Bone Spine"},{"key":"3952_CR108","doi-asserted-by":"crossref","unstructured":"Feng J, Jiang Y, Wang O, Li M, Xing X, ping, Meng X wu, Xia W. The analysis of missed diagnosis and misdiagnosis of 144 tumor-induced osteomalacia patients. Bone Abstracts. 2016;5:92.","DOI":"10.1530\/boneabs.5.P92"},{"key":"3952_CR109","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.bonr.2022.101180","volume":"16","author":"L Filipov\u00e1","year":"2022","unstructured":"Filipov\u00e1 L, Zik\u00e1n V, Krsek M, Netuka D, Michal M, Laz\u00farov\u00e1 I. Tumor induced osteomalacia - A long way toward correct diagnosis and management. Bone Rep. 2022;16:101180.","journal-title":"Bone Rep"},{"issue":"12","key":"3952_CR110","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/medicina58121875","volume":"58","author":"E Musacchio","year":"2022","unstructured":"Musacchio E, Michielin A, Sartori L. Misdiagnosis and mistreatment of a rare case of intracranial oncogenic osteomalacia with an altered amino acid profile. Medicina. 2022;58(12):1875.","journal-title":"Medicina"},{"issue":"1","key":"3952_CR111","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00223-025-01374-w","volume":"116","author":"I B\u00f6ckmann","year":"2025","unstructured":"B\u00f6ckmann I, Haffner D. The diagnosis and therapy of XLH. Calcif Tissue Int. 2025;116(1):66.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"3952_CR112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","volume":"16","author":"F Al Juraibah","year":"2021","unstructured":"Al Juraibah F, Al Amiri E, Al Dubayee M, Al Jubeh J, Al Kandari H, Al Sagheir A, Al Shaikh A, Beshyah SA, Deeb A, Habeb A, Mustafa M, Zidan H, Mughal MZ. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries. Arch Osteoporos. 2021;16(1):52.","journal-title":"Arch Osteoporos"},{"key":"3952_CR113","doi-asserted-by":"publisher","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","volume":"12","author":"MR Laurent","year":"2021","unstructured":"Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, Bravenboer B, Velkeniers B, Lammens J, Harvengt P, Cavalier E, Kaux JF, Lombet J, De Waele K, Verroken C, Van Hoeck K, Mortier GR, Levtchenko E. Vande Walle J. Consensus recommendations for the diagnosis and management of X-Linked hypophosphatemia in Belgium. Front Endocrinol. 2021;12:641543.","journal-title":"Front Endocrinol"},{"issue":"1","key":"3952_CR114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbmr.4486","volume":"37","author":"F Aljuraibah","year":"2020","unstructured":"Aljuraibah F, Bacchetta J, Brandi ML, Florenzano P, Javaid MK, M\u00e4kitie O, Raimann A, Rodriguez M, Siggelkow H, Tiosano D, Vervloet M, Wagner CA. An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia. J Bone Min Res. 2020;37(1):12\u201320.","journal-title":"J Bone Min Res"},{"issue":"3","key":"3952_CR115","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","volume":"105","author":"S Hawley","year":"2020","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, Javaid MK. Prevalence and mortality of individuals with X-Linked hypophosphatemia: A united Kingdom Real-World data analysis. J Clin Endocrinol Metab. 2020;105(3):e871\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"3952_CR116","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/jbmr.4702","volume":"37","author":"IR Hartley","year":"2020","unstructured":"Hartley IR, Gafni RI, Roszko KL, Brown SM, De Castro LF, Saikali A, Ferreira CR, Gahl WA, Pacak K, Blau JE, Boyce AM, Salusky IB, Collins MT, Florenzano P. Determination of FGF23 levels for the diagnosis of FGF23-Mediated hypophosphatemia. J Bone Min Res. 2020;37(11):2174\u201385.","journal-title":"J Bone Min Res"},{"issue":"5","key":"3952_CR117","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","volume":"101","author":"JC Souberbielle","year":"2017","unstructured":"Souberbielle JC, Pri\u00e9 D, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, Cavalier E. Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int. 2017;101(5):510\u20138.","journal-title":"Calcif Tissue Int"},{"key":"3952_CR118","doi-asserted-by":"publisher","first-page":"104958","DOI":"10.1016\/j.ejmg.2024.104958","volume":"70","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Grandone A, Aversa A, Sessa MR, Pelosini C, Michelucci A, Toschi B, Manca M, Isola A, Comberiati P. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets. Eur J Med Genet. 2024;70:104958.","journal-title":"Eur J Med Genet"},{"key":"3952_CR119","doi-asserted-by":"publisher","first-page":"101819","DOI":"10.1016\/j.bonr.2024.101819","volume":"24","author":"C Jarvis","year":"2025","unstructured":"Jarvis C, Ramakrishnan R, Dharmaraj P, Mushtaq T, Gupta S, Williams A, Rylands AJ, Barham H, Nixon A, Uday S. Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH). Bone Rep. 2025;24:101819.","journal-title":"Bone Rep"},{"issue":"3","key":"3952_CR120","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","volume":"107","author":"K Dahir","year":"2022","unstructured":"Dahir K, Dhaliwal R, Simmons J, Imel EA, Gottesman GS, Mahan JD, Prakasam G, Hoch AI, Ramesan P. D\u00edaz-Gonz\u00e1lez de Ferris M. Health care transition from Pediatric- to Adult-Focused care in X-linked hypophosphatemia: expert consensus. J Clin Endocrinol Metab. 2022;107(3):599\u2013613.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3952_CR121","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/endocrines3030032","volume":"3","author":"T Kubota","year":"2022","unstructured":"Kubota T. X-Linked hypophosphatemia transition and team management. Endocrines. 2022;3(3):411\u20138.","journal-title":"Endocrines"},{"issue":"S2","key":"3952_CR122","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-023-02883-3","volume":"18","author":"L Seefried","year":"2023","unstructured":"Seefried L, Alzahrani A, Arango Sancho P, Bacchetta J, Crowley R, Emma F, Gibbins J, Grandone A, Javaid MK, Mindler G, Raimann A, Rothenbuhler A, Tucker I, Zeitlin L, Linglart A. XLH matters 2022: insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH). Orphanet J Rare Dis. 2023;18(S2):333.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3952_CR123","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"ML Piketty","year":"2020","unstructured":"Piketty ML, Brabant S, Souberbielle JC, Maruani G, Audrain C, Rothenbuhler A, Pri\u00e9 D, Linglart A. FGF23 measurement in burosumab-treated patients: an emerging treatment May induce a new analytical interference. Clin Chem Lab Med. 2020;58(11):e267\u20139.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"3952_CR124","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1210\/jc.2013-4515","volume":"99","author":"S Jadhav","year":"2014","unstructured":"Jadhav S, Kasaliwal R, Shetty NS, Kulkarni S, Rathod K, Popat B, Kakade H, Bukan A, Khare S, Budyal S, Jagtap VS, Lila AR, Bandgar T, Shah NS. Radiofrequency ablation, an effective modality of treatment in Tumor-Induced osteomalacia: A case series of three patients. J Clin Endocrinol Metab. 2014;99(9):3049\u201354.","journal-title":"J Clin Endocrinol Metab"},{"key":"3952_CR125","doi-asserted-by":"publisher","first-page":"688309","DOI":"10.3389\/fendo.2021.688309","volume":"12","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Mora S. X-Linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol. 2021;12:688309.","journal-title":"Front Endocrinol"},{"issue":"02","key":"3952_CR126","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1055\/s-0040-1721400","volume":"11","author":"A Deeb","year":"2022","unstructured":"Deeb A, Juraibah FA, Dubayee MA, Habeb A. X-linked hypophosphatemic rickets: awareness, knowledge, and practice of pediatric endocrinologists in Arab countries. J Pediatr Genet. 2022;11(02):126\u201331.","journal-title":"J Pediatr Genet"},{"issue":"07","key":"3952_CR127","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5414\/CN109069","volume":"88","author":"K Phelps","year":"2017","unstructured":"Phelps K, Mason D. Evidence that tmp\/gfr can be estimated with the Walton-Bijvoet nomogram in chronic kidney disease. Clin Nephrol. 2017;88(07):19\u201328.","journal-title":"Clin Nephrol"},{"issue":"2","key":"3952_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00862587","volume":"2","author":"J Brodehl","year":"1988","unstructured":"Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol. 1988;2(2):183\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"3952_CR129","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s00330-020-07342-2","volume":"31","author":"Q He","year":"2021","unstructured":"He Q, Zhang B, Zhang L, Chen Z, Shi X, Yi C, Wang X, Zhang X. Diagnostic efficiency of 68Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia. Eur Radiol. 2021;31(4):2414\u201321.","journal-title":"Eur Radiol"},{"issue":"4","key":"3952_CR130","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MNM.0000000000001163","volume":"41","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Hou G, Cheng W. Performance of 68Ga-DOTA-SST PET\/CT, Octreoscan SPECT\/CT and 18F-FDG PET\/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis. Nucl Med Commun. 2020;41(4):370\u20136.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"3952_CR131","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A. Head-to-Head comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET\/CT: A prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"3952_CR132","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/diagnostics10010002","volume":"10","author":"M Meyer","year":"2019","unstructured":"Meyer M, Nicod Lalonde M, Testart N, Jreige M, Kamani C, Boughdad S, Muoio B, Becce F, Schaefer N, Candrian C, Giovanella L, Prior JO, Treglia G, Riegger M. Detection rate of culprit tumors causing osteomalacia using somatostatin receptor PET\/CT: systematic review and Meta-Analysis. Diagnostics. 2019;10(1):2.","journal-title":"Diagnostics"},{"issue":"4","key":"3952_CR133","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/apa.15617","volume":"110","author":"O Kvist","year":"2021","unstructured":"Kvist O, Luiza Dallora A, Nilsson O, Anderberg P, Sanmartin Berglund J, Flodmark C, Diaz S. A cross-sectional magnetic resonance imaging study of factors influencing growth plate closure in adolescents and young adults. Acta Paediatr. 2021;110(4):1249\u201356.","journal-title":"Acta Paediatr"},{"issue":"4","key":"3952_CR134","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000464142","volume":"87","author":"M Lempicki","year":"2017","unstructured":"Lempicki M, Rothenbuhler A, Merzoug V, Franchi-Abella S, Chaussain C, Adamsbaum C, Linglart A. Magnetic resonance imaging features as surrogate markers of X-Linked hypophosphatemic rickets activity. Horm Res Paediatr. 2017;87(4):244\u201353.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"3952_CR135","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-21-0429","volume":"185","author":"VV Zhukouskaya","year":"2021","unstructured":"Zhukouskaya VV, Mannes I, Chaussain C, Kamenick\u00fd P, Audrain C, Lambert AS, Nevoux J, Wicart P, Briot K, Di Rocco F, Trabado S, Pri\u00e9 D, Di Somma C, Colao A, Adamsbaum C, Rothenbuhler A, Linglart A. Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. Eur J Endocrinol. 2021;185(4):475\u201384.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3952_CR136","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/endocrines3030030","volume":"3","author":"N Ito","year":"2022","unstructured":"Ito N. Adult presentation of X-Linked hypophosphatemia. Endocrines. 2022;3(3):375\u201390.","journal-title":"Endocrines"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03952-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:23:51Z","timestamp":1781609031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-03952-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3952"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03952-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MLB declares honoraria from Amgen, Ascendis, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants and\/or speaker fees from Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa Therapeutics, SPA, Takeda, Theramex, UCB, and consultant fees from Aboca, Alexion, Amolyt, Brun Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, Smoke Free World Foundation; CEV declares speaker and\/or consulting fees from Kyowa Kirin; AG declares speaker and\/or consulting fees from Kyowa Kirin, AMGEN, UCB, Abiogen, Latin Pharma; SM served as speaker for Abiogen, Beijing Society Biomedical Engineering, Bruno Farmaceutici, Diasorin, Geopharma, Sandoz, UCB and served in the advisory board of Abiogen, Ely Lilli, Kyowa Kirin, Faes Farm., Novo Nordisk, UCB; DF, AM and SG report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}